UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

American journal of nephrology, 2019-06, Vol.49 (6), p.470-478

2019

Volltextzugriff (PDF)

An insight into the presence of impurities in reference standards and their impact on mass spectrometry-based bioanalysis

Bioanalysis, 2022-09, Vol.14 (18), p.1191-1195

2022

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

Naunyn-Schmiedeberg's archives of pharmacology, 2024-07, Vol.397 (7), p.4737-4745

2024

Volltextzugriff (PDF)

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC–MS/MS, a novel antimalarial compound

Bioanalysis, 2021-12, Vol.13 (23), p.1761-1777

2021

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Clinical pharmacology in drug development, 2023-02, Vol.12 (2), p.202-211

2023

Volltextzugriff (PDF)

Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia

Frontiers in Nephrology (Online), 2024-10, Vol.4

2024

Volltextzugriff (PDF)

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

Clinical pharmacokinetics, 2018-01, Vol.57 (1), p.87-102

2018

Volltextzugriff (PDF)

Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs

Drug development and industrial pharmacy, 2019-09, Vol.45 (9), p.1459-1467

2019

Volltextzugriff (PDF)

Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies - Review of Case Studies

Drug metabolism letters, 2019, Vol.13 (1), p.3-18

2019

Volltextzugriff (PDF)

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase‐4, for the treatment of Type 2 diabetes mellitus

British journal of pharmacology, 2017-07, Vol.174 (14), p.2346-2357

2017

Volltextzugriff (PDF)

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

Clinical drug investigation, 2018, Vol.38 (1), p.57-65

2018

Volltextzugriff (PDF)

Synthesis and structure–activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element

European journal of medicinal chemistry, 2012-12, Vol.58, p.136-152

2012

Volltextzugriff (PDF)

Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist

ACS medicinal chemistry letters, 2016-01, Vol.7 (1), p.51-55

2016

Volltextzugriff (PDF)

Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives

Biomedical chromatography, 2017-01, Vol.31 (1), p.np-n/a

2017

Volltextzugriff (PDF)

Discovery of Orally Active, Potent, and Selective Benzotriazole-Based PTP1B Inhibitors

ChemMedChem, 2011-06, Vol.6 (6), p.1011-1016

2011

Volltextzugriff (PDF)

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment

Clinical pharmacology and therapeutics, 2024-10

2024

Volltextzugriff (PDF)

A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson’s disease

Brain research, 2024-11, Vol.1842, p.149129, Article 149129

2024

Volltextzugriff (PDF)

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021-11, Vol.1185, p.122982-122982, Article 122982

2021

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes

Clinical pharmacology in drug development, 2024-02, Vol.13 (2), p.152-159

2024

Volltextzugriff (PDF)

A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)

Clinical infectious diseases, 2021-11, Vol.73 (9), p.e2722-e2728

2021

Volltextzugriff (PDF)

Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

European journal of drug metabolism and pharmacokinetics, 2022-09, Vol.47 (5), p.725-740

2022

Volltextzugriff (PDF)

Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment

Clinical pharmacology in drug development, 2023-12, Vol.12 (12), p.1142-1155

2023

Volltextzugriff (PDF)

Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime

Drug research (Stuttgart), 2019-05, Vol.69 (5), p.245-255

2019

Volltextzugriff (PDF)

Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes

Bioorganic & medicinal chemistry, 2021-04, Vol.35, p.116071-116071, Article 116071

2021

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(75)
Dissertationen
(2)

Sprache

Englisch
(77)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

An insight into the presence of impurities in reference standards and their impact on mass spectrometry-based bioanalysis

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC–MS/MS, a novel antimalarial compound

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs

Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies - Review of Case Studies

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase‐4, for the treatment of Type 2 diabetes mellitus

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects

Synthesis and structure–activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: Application of weakly basic sulfoximine group as novel S4 binding element

Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist

Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives

Discovery of Orally Active, Potent, and Selective Benzotriazole-Based PTP1B Inhibitors

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment

A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson’s disease

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes

A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)

Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study

Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment

Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime

Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes

Suchergebnisse filtern